Compare Amphastar Pharmaceuticals Inc (AMPH) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Manulife Financial Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Manulife Financial Corporation trades at $41.29 (market cap $68.50B). The key difference: Manulife Financial Corporation is far larger — about 82.9× Amphastar Pharmaceuticals Inc's market cap, and Manulife Financial Corporation pays a 3.23% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MFC | |
|---|---|---|
Market Cap | $826.08M | $68.50B |
Sector | Health | Financials |
52-Week High | $30.81 | $41.49 |
52-Week Low | $16.87 | $29.90 |
Enterprise Value | $1.22B | $65.07B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Manulife Financial (MFC) trades at $41.29, down 0.48% with a bullish technical outlook. The stock shows solid fundamentals with revenue growth to $53.01B in 2025 and net income of $5.78B, though Q1 2026 earnings missed expectations. Analyst consensus is strongly bullish with 57% buy ratings, supported by positive AI developments and dividend payments.
MFC presents a compelling investment case with strong profitability metrics (ROE 13.14%) and reasonable valuation (P/E 16.89). Key risks include regulatory scrutiny in Hong Kong and wealth management outflows. The company's AI leadership and Asia growth provide upside potential, though investors should monitor execution on recent strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
